Curative treatments in oligometastatic bone disease (2025) – online course
Description
Authors: J. Garnon and D. Filippiadis
Reviewers: F. Deschamps, M. Hoffmann, T. Jahnke, G. Mauri, C. Nice, R. Uberoi
This course corresponds to chapter 2.2.4.2 Percutaneous ablation of bone and soft tissue lesions in the European Curriculum and Syllabus for Interventional Radiology.
Abstract
Metastatic bone disease is most seen with specific cancer types, including those arising from breast, prostate, lung, and kidney, whilst multiple myeloma seems to be the most common of hematologic malignancies. New systemic treatments may render a wider range of patients prone to becoming oligometastatic; in these patients, local therapies combined with systemic therapies are likely to play an important role in oncologic management. Per-cutaneous thermal ablation by means of radiofrequency, cryoablation, or microwave ener-gy can be used as a curative therapy in oligometastatic bone disease aiming to achieve local tumour control. According to the National Comprehensive Cancer Network (NCCN) guidelines, ablation for adult cancer pain can be proposed when there is no oncologic emergency (e.g., pathologic fracture or epidural disease) or when the pharmacologic ther-apy is inadequate, and radiation therapy is contraindicated or not desired by the patient. Additionally, percutaneous thermal ablation can be offered with curative or palliative intent in case of radiation therapy relapses or failures. During thermal ablation, irreversible ther-mal damage and coagulation necrosis are achieved by energy application. A treatment algorithm is necessary for the indication of ablation in bone metastases and for combining ablation with bone augmentation in weight-bearing locations and long bones.
Learning objectives
- Define the actual indications and limits of percutaneous ablation as a curative treatment in ologometastatic bone diseases
- Describe the available ablative techniques
- Describe how to make an optimal choice of ablation technology
- Describe the patient pathway and the follow-up
- Describe the collaboration with other specialists
Further information
This course covers a basic level of IR knowledge and is designed for trainees, students or young consultants aiming to acquire essential knowledge or prepare for the EBIR exam. Thereby, it is tailored to the European Curriculum and Syllabus for Interventional Radiology and corresponds to chapter 2.2.4.2 Percutaneous ablation of bone and soft tissue lesions.
The format of the course is interactive and easy to use, including texts, graphics, videos and a quiz to support your learning. The course duration is around one hour and is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to award 1 European CME credit (ECMEC). The CME accreditation for this course will expire on January 27, 2027. A non-CME accredited version of the course will remain available until January 27, 2029.
The acquired CME Certificate will be available in the myCIRSE area under CIRSE Academy.
The enrolment period of this course is linked to the validity of the All-Access Pass.
Release date: January 2025
